X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accesswire.com/846779/protagonist-therapeutics-provides-update-on-verify-patient-enrollment-and-timing-of-top-line-data
https://www.accesswire.com/843636/protagonist-therapeutics-announces-closing-of-worldwide-rusfertide-license-and-collaboration-agreement-with-takeda
https://www.accesswire.com/841100/late-breaking-presentation-at-american-academy-of-dermatology-2024-annual-meeting-shows-that-jnj-2113-the-first-and-only-investigational-targeted-oral-peptide-maintained-skin-clearance-in-moderate-to-severe-plaque-psoriasis-through-one-year
https://www.accesswire.com/840017/protagonist-therapeutics-to-participate-in-upcoming-investor-conferences
https://endpts.com/takeda-pays-protagonist-300m-upfront-to-co-develop-co-commercialize-rare-disease-drug-rusfertide/
https://feeds.issuerdirect.com/news-release.html?newsid=7580845453930559
Market Place
Share 
